<p>Rallybio Corporation（纳斯达克代码：RLYB - 获取免费报告）主要股东 Adar1 Capital Management, Llc 于 5 月 19 日（星期二）购买了 10,200 股该公司的股票。每股购买价格为 13.98 美元，总价值为 142,596.00 美元。收购后，该内部人士直接持有 926,352 股公司股票，估值约为 12,950,400.96 美元。此交易代表其持股比例增加了 1.11%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接访问。持有公司至少 10% 股份的主要股东需向 SEC 披露其交易。</p>
<p>Adar1 Capital Management, Llc 最近还进行了以下交易：</p>
<ul>
<li>5 月 18 日（星期一），Adar1 Capital Management, Llc 购买了 6,009 股 Rallybio 股票。每股购买成本为 13.98 美元，总交易额为 84,005.82 美元。</li>
<li>5 月 15 日（星期五），Adar1 Capital Management, Llc 购买了 300 股 Rallybio 股票。每股购买成本为 13.90 美元，总价值为 4,170.00 美元。</li>
<li>5 月 13 日（星期三），Adar1 Capital Management, Llc 购买了 79,259 股 Rallybio 股票。每股购买价格为 13.99 美元，总价值为 1,108,833.41 美元。</li>
<li>5 月 12 日（星期二），Adar1 Capital Management, Llc 购买了 800 股 Rallybio 股票。每股购买价格为 13.83 美元，总价值为 11,064.00 美元。</li>
<li>5 月 11 日（星期一），Adar1 Capital Management, Llc 收购了 50,000 股 Rallybio 股票。每股收购成本为 14.00 美元，总价值为 700,000.00 美元。</li>
<li>5 月 5 日（星期二），Adar1 Capital Management, Llc 收购了 35,101 股 Rallybio 股票。每股收购成本为 14.00 美元，总价值为 491,414.00 美元。</li>
<li>5 月 4 日（星期一），Adar1 Capital Management, Llc 购买了 120,804 股 Rallybio 股票。每股购买成本为 13.97 美元，总价值为 1,687,631.88 美元。</li>
</ul>
<h2>Rallybio 股票上涨 2.7%</h2>
<p>在周三的午盘交易中，RLYB 的股票上涨了 0.39 美元，达到 14.58 美元。该股票的交易量为 43,720 股，而其平均交易量为 642,666 股。Rallybio Corporation 的 12 个月最低价为 2.16 美元，最高价为 15.31 美元。该公司的 50 日简单移动平均为 10.05 美元，200 日简单移动平均为 7.25 美元。公司的市值为 7727 万美元，市盈率为-3.20，贝塔值为-1.10。</p>
<p>Rallybio（纳斯达克代码：RLYB - 获取免费报告）最近于 5 月 13 日（星期三）发布了季度财报。公司报告每股收益为（1.46 美元），低于分析师一致预期的（1.20 美元），差额为（0.26 美元）。Rallybio 的净利润率为-911.07%，股本回报率为-55.79%。该公司在本季度的收入为 21 万美元，而一致预期为 21 万美元。</p>
<h2>分析师评级调整</h2>
<p>RLYB 最近成为几份研究报告的主题。华尔街 Zen 在 3 月 28 日（星期六）的报告中将 Rallybio 的评级上调至 “持有”。Weiss Ratings 在 5 月 8 日（星期五）的研究报告中重申了对 Rallybio 股票的 “卖出（d-）” 评级。根据 MarketBeat 的数据，一位股票研究分析师对该股票给予了 “卖出” 评级，Rallybio 的平均评级为 “卖出”。</p>
<p><strong>查看我们最新的 RLYB 股票报告</strong></p>
<h2>机构投资者对 Rallybio 的看法</h2>
<p>一些机构投资者最近对该股票的持仓进行了调整。XTX Topco Ltd 在第四季度将其在 Rallybio 的持仓增加了 64.6%。XTX Topco Ltd 现在拥有 97,313 股公司股票，价值 67,000 美元，在此期间又购买了 38,205 股。Susquehanna International Group LLP 在第三季度将其在 Rallybio 的持仓增加了 485.9%。Susquehanna International Group LLP 现在拥有 136,294 股公司股票，价值 68,000 美元，在此期间又购买了 113,031 股。Geode Capital Management LLC 在第四季度将其在 Rallybio 的持仓增加了 1.2%。Geode Capital Management LLC 现在拥有 248,005 股公司股票，价值 170,000 美元，在此期间又购买了 2,996 股。Citadel Advisors LLC 在第三季度将其在 Rallybio 的持仓增加了 576.1%。Citadel Advisors LLC 现在拥有 438,705 股公司股票，价值 219,000 美元，在此期间又购买了 373,821 股。最后，Renaissance Technologies LLC 在第四季度将其在 Rallybio 的持仓增加了 16.9%。Renaissance Technologies LLC 现在拥有 835,692 股公司股票，价值 573,000 美元，在此期间又购买了 120,892 股。90.34% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Rallybio</h2>
<p>（获取免费报告）</p>
<p>Rallybio Therapeutics, Inc（纳斯达克代码：RLYB）是一家临床阶段的生物技术公司，专注于开发和商业化针对罕见遗传疾病患者的治疗方案。该公司的科学方法利用多种模式，包括单克隆抗体、小分子和酶替代，以解决免疫缺陷、代谢紊乱和皮肤病等领域的高未满足需求的疾病。Rallybio 的产品线旨在通过注册临床试验推进，目标是为目前缺乏或没有批准治疗方案的患者提供首创或最佳治疗。</p>
<p>Rallybio 的主要项目之一是 RBX-100，一种针对先天性无胸腺症的研究性疗法，这是一种罕见的儿童免疫缺陷病。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Rallybio 更好</li>
<li>从 Zepbound 到 Foundayo：礼来最新业绩支持口服 GLP-1 前景</li>
<li>人工智能整合开始：黑石与谷歌打造人工智能帝国</li>
<li>美国稀土公司在 2026 年第一季度表现强劲，巨额 Serra Vera 交易即将达成</li>
<li>3 只太空基础设施股票在 SpaceX IPO 前获得动能</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxZQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxZQg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Rallybio 吗？</h2>
<p>在你考虑 Rallybio 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Rallybio 并不在名单上。</p>
<p>虽然 Rallybio 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RLYB

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

<p>Adar1 Capital Management，Rallybio Corporation（NASDAQ:RLYB）的主要股东，购买了 10,200 股，每股价格为 13.98 美元，总计 142,596 美元。这次收购使他们的持股比例增加了 1.11%，使其总持股达到 926,352 股，估值约为 1295 万美元。该交易已按照主要股东的要求向 SEC 披露。在午盘交易中，Rallybio 的股票上涨了 2.7%，达到 14.58 美元</p>

<p>Rallybio Corporation (NASDAQ:RLYB - Get Free Report) major shareholder Adar1 Capital Management, Llc bought 10,200 shares of the firm's stock in a transaction dated Tuesday, May 19th. The shares were purchased at an average price of $13.98 per share, with a total value of $142,596.00. Following the acquisition, the insider directly owned 926,352 shares in the company, valued at approximately $12,950,400.96. This trade represents a 1.11% increase in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.</p>
<div class="lb-trans"><p>Rallybio Corporation（纳斯达克代码：RLYB - 获取免费报告）主要股东 Adar1 Capital Management, Llc 于 5 月 19 日（星期二）购买了 10,200 股该公司的股票。每股购买价格为 13.98 美元，总价值为 142,596.00 美元。收购后，该内部人士直接持有 926,352 股公司股票，估值约为 12,950,400.96 美元。此交易代表其持股比例增加了 1.11%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接访问。持有公司至少 10% 股份的主要股东需向 SEC 披露其交易。</p>
</div><p>Adar1 Capital Management, Llc also recently made the following trade(s):</p>
<div class="lb-trans"><p>Adar1 Capital Management, Llc 最近还进行了以下交易：</p>
</div><ul>
<li>On Monday, May 18th, Adar1 Capital Management, Llc purchased 6,009 shares of Rallybio stock. The shares were purchased at an average cost of $13.98 per share, for a total transaction of $84,005.82.</li>
<li>On Friday, May 15th, Adar1 Capital Management, Llc purchased 300 shares of Rallybio stock. The stock was acquired at an average cost of $13.90 per share, with a total value of $4,170.00.</li>
<li>On Wednesday, May 13th, Adar1 Capital Management, Llc purchased 79,259 shares of Rallybio stock. The stock was bought at an average price of $13.99 per share, with a total value of $1,108,833.41.</li>
<li>On Tuesday, May 12th, Adar1 Capital Management, Llc purchased 800 shares of Rallybio stock. The stock was bought at an average price of $13.83 per share, with a total value of $11,064.00.</li>
<li>On Monday, May 11th, Adar1 Capital Management, Llc acquired 50,000 shares of Rallybio stock. The stock was acquired at an average cost of $14.00 per share, with a total value of $700,000.00.</li>
<li>On Tuesday, May 5th, Adar1 Capital Management, Llc acquired 35,101 shares of Rallybio stock. The stock was acquired at an average cost of $14.00 per share, with a total value of $491,414.00.</li>
<li>On Monday, May 4th, Adar1 Capital Management, Llc purchased 120,804 shares of Rallybio stock. The shares were purchased at an average cost of $13.97 per share, with a total value of $1,687,631.88.</li>
</ul>
<div class="lb-trans"><ul>
<li>5 月 18 日（星期一），Adar1 Capital Management, Llc 购买了 6,009 股 Rallybio 股票。每股购买成本为 13.98 美元，总交易额为 84,005.82 美元。</li>
<li>5 月 15 日（星期五），Adar1 Capital Management, Llc 购买了 300 股 Rallybio 股票。每股购买成本为 13.90 美元，总价值为 4,170.00 美元。</li>
<li>5 月 13 日（星期三），Adar1 Capital Management, Llc 购买了 79,259 股 Rallybio 股票。每股购买价格为 13.99 美元，总价值为 1,108,833.41 美元。</li>
<li>5 月 12 日（星期二），Adar1 Capital Management, Llc 购买了 800 股 Rallybio 股票。每股购买价格为 13.83 美元，总价值为 11,064.00 美元。</li>
<li>5 月 11 日（星期一），Adar1 Capital Management, Llc 收购了 50,000 股 Rallybio 股票。每股收购成本为 14.00 美元，总价值为 700,000.00 美元。</li>
<li>5 月 5 日（星期二），Adar1 Capital Management, Llc 收购了 35,101 股 Rallybio 股票。每股收购成本为 14.00 美元，总价值为 491,414.00 美元。</li>
<li>5 月 4 日（星期一），Adar1 Capital Management, Llc 购买了 120,804 股 Rallybio 股票。每股购买成本为 13.97 美元，总价值为 1,687,631.88 美元。</li>
</ul>
</div><h2>Rallybio Stock Up 2.7%</h2>
<div class="lb-trans"><h2>Rallybio 股票上涨 2.7%</h2>
</div><p>Shares of RLYB traded up $0.39 during midday trading on Wednesday, reaching $14.58. 43,720 shares of the stock were exchanged, compared to its average volume of 642,666. Rallybio Corporation has a 12-month low of $2.16 and a 12-month high of $15.31. The firm has a 50 day simple moving average of $10.05 and a 200-day simple moving average of $7.25. The company has a market cap of $77.27 million, a price-to-earnings ratio of -3.20 and a beta of -1.10.</p>
<div class="lb-trans"><p>在周三的午盘交易中，RLYB 的股票上涨了 0.39 美元，达到 14.58 美元。该股票的交易量为 43,720 股，而其平均交易量为 642,666 股。Rallybio Corporation 的 12 个月最低价为 2.16 美元，最高价为 15.31 美元。该公司的 50 日简单移动平均为 10.05 美元，200 日简单移动平均为 7.25 美元。公司的市值为 7727 万美元，市盈率为-3.20，贝塔值为-1.10。</p>
</div><p>Rallybio (NASDAQ:RLYB - Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.26). Rallybio had a negative net margin of 911.07% and a negative return on equity of 55.79%. The company had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.21 million.</p>
<div class="lb-trans"><p>Rallybio（纳斯达克代码：RLYB - 获取免费报告）最近于 5 月 13 日（星期三）发布了季度财报。公司报告每股收益为（1.46 美元），低于分析师一致预期的（1.20 美元），差额为（0.26 美元）。Rallybio 的净利润率为-911.07%，股本回报率为-55.79%。该公司在本季度的收入为 21 万美元，而一致预期为 21 万美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>RLYB has been the topic of several recent research reports. Wall Street Zen raised Rallybio to a &#34;hold&#34; rating in a report on Saturday, March 28th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Rallybio in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Rallybio has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>RLYB 最近成为几份研究报告的主题。华尔街 Zen 在 3 月 28 日（星期六）的报告中将 Rallybio 的评级上调至 “持有”。Weiss Ratings 在 5 月 8 日（星期五）的研究报告中重申了对 Rallybio 股票的 “卖出（d-）” 评级。根据 MarketBeat 的数据，一位股票研究分析师对该股票给予了 “卖出” 评级，Rallybio 的平均评级为 “卖出”。</p>
</div><p><strong>View Our Latest Stock Report on RLYB</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 RLYB 股票报告</strong></p>
</div><h2>Institutional Investors Weigh In On Rallybio</h2>
<div class="lb-trans"><h2>机构投资者对 Rallybio 的看法</h2>
</div><p>A number of institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd boosted its position in shares of Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company's stock worth $67,000 after buying an additional 38,205 shares during the period. Susquehanna International Group LLP boosted its position in shares of Rallybio by 485.9% during the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company's stock worth $68,000 after buying an additional 113,031 shares during the period. Geode Capital Management LLC boosted its position in shares of Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company's stock worth $170,000 after buying an additional 2,996 shares during the period. Citadel Advisors LLC boosted its position in shares of Rallybio by 576.1% during the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company's stock worth $219,000 after buying an additional 373,821 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company's stock worth $573,000 after buying an additional 120,892 shares during the period. 90.34% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近对该股票的持仓进行了调整。XTX Topco Ltd 在第四季度将其在 Rallybio 的持仓增加了 64.6%。XTX Topco Ltd 现在拥有 97,313 股公司股票，价值 67,000 美元，在此期间又购买了 38,205 股。Susquehanna International Group LLP 在第三季度将其在 Rallybio 的持仓增加了 485.9%。Susquehanna International Group LLP 现在拥有 136,294 股公司股票，价值 68,000 美元，在此期间又购买了 113,031 股。Geode Capital Management LLC 在第四季度将其在 Rallybio 的持仓增加了 1.2%。Geode Capital Management LLC 现在拥有 248,005 股公司股票，价值 170,000 美元，在此期间又购买了 2,996 股。Citadel Advisors LLC 在第三季度将其在 Rallybio 的持仓增加了 576.1%。Citadel Advisors LLC 现在拥有 438,705 股公司股票，价值 219,000 美元，在此期间又购买了 373,821 股。最后，Renaissance Technologies LLC 在第四季度将其在 Rallybio 的持仓增加了 16.9%。Renaissance Technologies LLC 现在拥有 835,692 股公司股票，价值 573,000 美元，在此期间又购买了 120,892 股。90.34% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Rallybio</h2>
<div class="lb-trans"><h2>关于 Rallybio</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Rallybio Therapeutics, Inc NASDAQ: RLYB is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company's scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio's pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.</p>
<div class="lb-trans"><p>Rallybio Therapeutics, Inc（纳斯达克代码：RLYB）是一家临床阶段的生物技术公司，专注于开发和商业化针对罕见遗传疾病患者的治疗方案。该公司的科学方法利用多种模式，包括单克隆抗体、小分子和酶替代，以解决免疫缺陷、代谢紊乱和皮肤病等领域的高未满足需求的疾病。Rallybio 的产品线旨在通过注册临床试验推进，目标是为目前缺乏或没有批准治疗方案的患者提供首创或最佳治疗。</p>
</div><p>Among Rallybio's lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.</p>
<div class="lb-trans"><p>Rallybio 的主要项目之一是 RBX-100，一种针对先天性无胸腺症的研究性疗法，这是一种罕见的儿童免疫缺陷病。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Rallybio</li>
<li>From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook</li>
<li>AI Consolidation Begins: Blackstone &amp; Google Forge an AI Empire</li>
<li>USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms</li>
<li>3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Rallybio 更好</li>
<li>从 Zepbound 到 Foundayo：礼来最新业绩支持口服 GLP-1 前景</li>
<li>人工智能整合开始：黑石与谷歌打造人工智能帝国</li>
<li>美国稀土公司在 2026 年第一季度表现强劲，巨额 Serra Vera 交易即将达成</li>
<li>3 只太空基础设施股票在 SpaceX IPO 前获得动能</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxZQg" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=RLYB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Rallybio Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Rallybio 吗？</h2>
</div><p>Before you consider Rallybio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Rallybio 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rallybio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Rallybio 并不在名单上。</p>
</div><p>While Rallybio currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Rallybio 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Insider Buying: Rallybio (NASDAQ:RLYB) Major Shareholder Buys 10,200 Shares of Stock

Market Beat

Rallybio

2 倍做多纳斯达克生物技术 ETF - ProShares

医疗业 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

标普全球医疗股指数 ETF - iShares

标普生物技术 ETF - SPDR

Invesco Nasdaq Biotechnology ETF

标普生物技术 3 倍做多 - Direxion

纳斯达克生物科技指数 ETF - iShares Nasdaq

美国制药 ETF - iShares

医疗业 ETF - Vanguard

基因改革 ETF - ARK

内部交易：Rallybio（纳斯达克代码：RLYB）的主要股东购买了 10,200 股股票